1)増田慎三.乳癌薬物療法の新展開—エベロリムス.日内分泌・甲状腺外会誌 32:80-85, 2015
2)Chia S, Gandhi S, Joy AA, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol 22:33-48, 2015
3)Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
4)Ito T, Okusaka T, Ikeda M, et al. Everolimus for advanced pancreatic neuroendocrine tumors:a sub-group analysis evaluating Japanese patients in the RADANT-3 trial. Jpn J Clin Oncol 42:903-911, 2012
5)伊藤鉄英,肱岡真之,李倫學,他.膵消化管神経内分泌腫瘍のUp to Date.日消誌 111:2255-2262, 2014
6)Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
7)山口和昭,栗原良平,勝良藍子,他.膵神経内分泌腫瘍に対するエベロリムス(アフィニトール)の長期投与時の安全性と有効性—PMS(Post-Marketing Surveillance)データの解析.胆と膵 40:561-568, 2019
8)大川清孝.消化管疾患:診断と鑑別の進め方—大腸潰瘍性病変の診断と鑑別 縦走潰瘍と輪状潰瘍の内視鏡的鑑別診断.胃と腸 50:1079-1086, 2015